PDF(Pubmed)
Abstract：
UNASSIGNED: This study aims to broaden the application of nano-contrast agents (NCAs) within the realm of the musculoskeletal system. It aims to introduce novel methods, strategies, and insights for the clinical management of ischemic muscle disorders, encompassing diagnosis, monitoring, evaluation, and therapeutic intervention.
UNASSIGNED: We developed a composite encapsulation technique employing O-carboxymethyl chitosan (OCMC) and liposome to encapsulate NCA-containing gold nanorods (GNRs) and perfluoropentane (PFP). This nanoscale contrast agent was thoroughly characterized for its basic physicochemical properties and performance. Its capabilities for in vivo and in vitro ultrasound imaging and photothermal imaging were authenticated, alongside a comprehensive biocompatibility assessment to ascertain its effects on microcirculatory perfusion in skeletal muscle using a murine model of hindlimb ischemia, and its potential to augment blood flow and facilitate recovery.
UNASSIGNED: The engineered GNR@OCMC-liposome/PFP nanostructure exhibited an average size of 203.18±1.49 nm, characterized by size uniformity, regular morphology, and a good biocompatibility profile. In vitro assessments revealed NCA\'s potent photothermal response and its transformation into microbubbles (MBs) under near-infrared (NIR) irradiation, thereby enhancing ultrasonographic visibility. Animal studies demonstrated the nanostructure\'s efficacy in photothermal imaging at ischemic loci in mouse hindlimbs, where NIR irradiation induced rapid temperature increases and significantly increased blood circulation.
UNASSIGNED: The dual-modal ultrasound/photothermal NCA, encapsulating GNR and PFP within a composite shell-core architecture, was synthesized successfully. It demonstrated exceptional stability, biocompatibility, and phase transition efficiency. Importantly, it facilitates the encapsulation of PFP, enabling both enhanced ultrasound imaging and photothermal imaging following NIR light exposure. This advancement provides a critical step towards the integrated diagnosis and treatment of ischemic muscle diseases, signifying a pivotal development in nanomedicine for musculoskeletal therapeutics.
UNASSIGNED: We developed a composite encapsulation technique employing O-carboxymethyl chitosan (OCMC) and liposome to encapsulate NCA-containing gold nanorods (GNRs) and perfluoropentane (PFP). This nanoscale contrast agent was thoroughly characterized for its basic physicochemical properties and performance. Its capabilities for in vivo and in vitro ultrasound imaging and photothermal imaging were authenticated, alongside a comprehensive biocompatibility assessment to ascertain its effects on microcirculatory perfusion in skeletal muscle using a murine model of hindlimb ischemia, and its potential to augment blood flow and facilitate recovery.
UNASSIGNED: The engineered GNR@OCMC-liposome/PFP nanostructure exhibited an average size of 203.18±1.49 nm, characterized by size uniformity, regular morphology, and a good biocompatibility profile. In vitro assessments revealed NCA\'s potent photothermal response and its transformation into microbubbles (MBs) under near-infrared (NIR) irradiation, thereby enhancing ultrasonographic visibility. Animal studies demonstrated the nanostructure\'s efficacy in photothermal imaging at ischemic loci in mouse hindlimbs, where NIR irradiation induced rapid temperature increases and significantly increased blood circulation.
UNASSIGNED: The dual-modal ultrasound/photothermal NCA, encapsulating GNR and PFP within a composite shell-core architecture, was synthesized successfully. It demonstrated exceptional stability, biocompatibility, and phase transition efficiency. Importantly, it facilitates the encapsulation of PFP, enabling both enhanced ultrasound imaging and photothermal imaging following NIR light exposure. This advancement provides a critical step towards the integrated diagnosis and treatment of ischemic muscle diseases, signifying a pivotal development in nanomedicine for musculoskeletal therapeutics.
摘要：
■本研究旨在扩大纳米造影剂（NCA）在肌肉骨骼系统领域的应用。它旨在介绍新颖的方法，战略,以及对缺血性肌肉疾病的临床管理的见解，包括诊断，监测,评估，和治疗干预。
■我们开发了一种复合封装技术，该技术采用O-羧甲基壳聚糖（OCMC）和脂质体来封装含NCA的金纳米棒（GNR）和全氟戊烷（PFP）。这种纳米级造影剂的基本理化性质和性能被彻底表征。其体内和体外超声成像和光热成像的能力得到了认证，除了使用后肢缺血的小鼠模型进行全面的生物相容性评估，以确定其对骨骼肌微循环灌注的影响，以及它增加血流量和促进恢复的潜力。
■工程GNR@OCMC-脂质体/PFP纳米结构的平均尺寸为203.18±1.49nm，以尺寸均匀为特征，规则的形态，和良好的生物相容性。体外评估显示NCA的有效光热响应及其在近红外（NIR）照射下转化为微泡（MBs），从而提高超声的可见度。动物研究证明了纳米结构在小鼠后肢缺血位点的光热成像中的功效，其中NIR照射引起温度快速升高并显着增加血液循环。
■双模态超声/光热NCA，将GNR和PFP封装在复合壳-核架构中，合成成功。它表现出非凡的稳定性，生物相容性，和相变效率。重要的是,它有助于PFP的封装，使增强超声成像和光热成像后的NIR曝光。这一进步为缺血性肌肉疾病的综合诊断和治疗提供了关键的一步，标志着肌肉骨骼疗法纳米医学的关键发展。
■我们开发了一种复合封装技术，该技术采用O-羧甲基壳聚糖（OCMC）和脂质体来封装含NCA的金纳米棒（GNR）和全氟戊烷（PFP）。这种纳米级造影剂的基本理化性质和性能被彻底表征。其体内和体外超声成像和光热成像的能力得到了认证，除了使用后肢缺血的小鼠模型进行全面的生物相容性评估，以确定其对骨骼肌微循环灌注的影响，以及它增加血流量和促进恢复的潜力。
■工程GNR@OCMC-脂质体/PFP纳米结构的平均尺寸为203.18±1.49nm，以尺寸均匀为特征，规则的形态，和良好的生物相容性。体外评估显示NCA的有效光热响应及其在近红外（NIR）照射下转化为微泡（MBs），从而提高超声的可见度。动物研究证明了纳米结构在小鼠后肢缺血位点的光热成像中的功效，其中NIR照射引起温度快速升高并显着增加血液循环。
■双模态超声/光热NCA，将GNR和PFP封装在复合壳-核架构中，合成成功。它表现出非凡的稳定性，生物相容性，和相变效率。重要的是,它有助于PFP的封装，使增强超声成像和光热成像后的NIR曝光。这一进步为缺血性肌肉疾病的综合诊断和治疗提供了关键的一步，标志着肌肉骨骼疗法纳米医学的关键发展。
